Racetam
Dimiracetam
SaveA racetam derivative studied in preclinical models for neuropathic and visceral pain. Shows activity at glutamatergic systems involved in central sensitization.
Quick verdict
Preclinical pain data is interesting and distinguishes it from other racetams, but no human efficacy data has been published.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Rodent studies show efficacy in chemotherapy-induced neuropathy and visceral pain models. Proposed mechanism involves modulation of spinal glutamatergic transmission. No published human trials.
Benefits
- Anti-nociceptive effects in rodent neuropathic pain models
- Potential for chemotherapy-induced neuropathy
Dosage notes
No human dosing established. Only used in animal research.
Side effects
- Unknown — no human data
Who should be cautious
Investigational compound. No human safety data published. Not available commercially.
What this page cannot tell you
All data is preclinical. Mechanism is interesting but unvalidated in humans.
Leaderboard scores
- Pain25
Write a review
Sign in to write a review.